TPWA
LGND icon

Twin Peaks Wealth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6K Buy
+73
New +$14.4K ﹤0.01% 856
2025
Q3 		– Sell
-45
Closed -$6.87K – 1255
2025
Q2 		$6.87K Buy
+45
New +$4.81K ﹤0.01% 1131

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Twin Peaks Wealth Advisors's LGND Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Ligand Pharmaceuticals (LGND) in Q1 2026: 73 shares worth $14.6K. The stake represents ﹤0.01% of the portfolio and ranks #856 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in LGND as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in LGND in Q2 2025 and has held it in 2 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Twin Peaks Wealth Advisors held 73 shares of Ligand Pharmaceuticals worth $14.6K as of Q1 2026.
  • Ligand Pharmaceuticals was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #856 holding.
  • Twin Peaks Wealth Advisors first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.